Skip to main content

Akcea Therapeutics, Inc.

Recalls

Recalls by year

A bar chart of the number of recalls naming this company by year.

Recalls by year
YearRecalls
20221
Download CSV

FDA Recall Terminated Historical recordClass I

Tegsedi (inotersen) Injection 284 mg/1.5 mL, Rx Only, Sterile solution for Subcutaneous Use, 4 prefilled syringes, each containing 284 mg of inotersen, (equivalent to 300 mg inotersen sodium in 1.5 ml of solution), Distributed by Sobi, Inc. Inc Waltham MA 02451, NDC: 72126-007-01

by Akcea Therapeutics, Inc.

Reason
Superpotent: High Out of specification (OOS) test result for percent label claim (%LC).
Published
July 6, 2022
Distribution
KY, USA

View recall →

Showing 1–1 of 1 results

This page lists recalls that name Akcea Therapeutics, Inc. as the recalling firm in the official source notice. It is not a safety rating, ranking, or statement that the company acted negligently. Read the full medical disclaimer.